Jean-Christophe Ianotto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jean-Christophe Ianotto has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
Christian Berthou
A Service d'Hématologie , Institut de Cancéro-Hématologie, Hôpital Morvan, CHRU de Brest , Brest Cedex , France
12 shared publicationsAdrian Tempescul
A Service d'Hématologie , Institut de Cancéro-Hématologie, Hôpital Morvan, CHRU de Brest , Brest Cedex , France
6 shared publicationsGaelle Guillerm
6 shared publications- Adrian Tempescul
University Hospital Brest
4 shared publications Jean-Richard Eveillard
Institut de Cancéro-Hématologie, Service d'hématologie, Hôpital Morvan, CHRU Brest, 29609 Brest Cedex, France
4 shared publicationsMarie-Anne Couturier
A Service d'Hématologie , Institut de Cancéro-Hématologie, Hôpital Morvan, CHRU de Brest , Brest Cedex , France
4 shared publications
Latest Publications
- 7 February 2017
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 58 (9) , 2258-2260
Biosimilars of filgrastim in autologous stem cell transplantation: certain differences for myeloma patients only
(2017). Biosimilars of filgrastim in autologous stem cell transplantation: certain differences for myeloma patients only. Leukemia & Lymphoma: Vol. 58, No. 9, pp. 2258-2260.
- 7 February 2017
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 58 (9) , 2258-2260
Biosimilars of filgrastim in autologous stem cell transplantation: certain differences for myeloma patients only
(2017). Biosimilars of filgrastim in autologous stem cell transplantation: certain differences for myeloma patients only. Leukemia & Lymphoma: Vol. 58, No. 9, pp. 2258-2260.
- 27 November 2015
- Published by Springer Nature in Annals of Hematology
- Vol. 95 (3) , 529-531
Extinction of myeloproliferative neoplasm by acquisition of a lymphoid disease: JAK2 V617F and JAK2 exon 12 allele burden disappearance during the follow-up of two patients
- 27 November 2015
- Published by Springer Nature in Annals of Hematology
- Vol. 95 (3) , 529-531
Extinction of myeloproliferative neoplasm by acquisition of a lymphoid disease: JAK2 V617F and JAK2 exon 12 allele burden disappearance during the follow-up of two patients
- 7 May 2013
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 55 (1) , 74-77
Biosimilars of filgrastim in autologous stem cell transplant: reduction in granulocyte-colony stimulating factor costs, but similar effects on bone marrow recovery
Granulocyte-colony stimulating factors (G-CSFs) enhance bone marrow (BM) recovery after autologous stem cell transplant (ASCT) in patients with lymphoma and myeloma. Few publications exist that discuss the use of filgrastim biosimilars after ASCT. We conducted a single-center retrospective study in patients with lymphoma and myeloma treated at Brest Hospital to assess the cost reductions related to and the efficiency and safety of filgrastim biosimilars. We identified 65 patients with lymphoma or myeloma treated with filgrastim biosimilars for ASCT and compared 19 parameters of these patients, including BM recovery, side effects, infectious complications and treatment costs, with published historical data on a cohort of 50 patients treated with classic filgrastim. We observed a significant reduction of G-CSF costs in both groups but did not observe a change in total hospitalization costs (representing less than 2% of the costs) between groups. Additionally, we did not observe differences between the two groups in BM recovery, infectious complications, side effects or the other studied parameters. In this retrospective study, the absence of differences between groups after ASCT in lymphoma and myeloma led us to believe that these drugs could be safely and effectively used for such indications without a significant impact on hospitalization costs. A prospective study should be conducted to confirm our results.
- 7 May 2013
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 55 (1) , 74-77
Biosimilars of filgrastim in autologous stem cell transplant: reduction in granulocyte-colony stimulating factor costs, but similar effects on bone marrow recovery
Granulocyte-colony stimulating factors (G-CSFs) enhance bone marrow (BM) recovery after autologous stem cell transplant (ASCT) in patients with lymphoma and myeloma. Few publications exist that discuss the use of filgrastim biosimilars after ASCT. We conducted a single-center retrospective study in patients with lymphoma and myeloma treated at Brest Hospital to assess the cost reductions related to and the efficiency and safety of filgrastim biosimilars. We identified 65 patients with lymphoma or myeloma treated with filgrastim biosimilars for ASCT and compared 19 parameters of these patients, including BM recovery, side effects, infectious complications and treatment costs, with published historical data on a cohort of 50 patients treated with classic filgrastim. We observed a significant reduction of G-CSF costs in both groups but did not observe a change in total hospitalization costs (representing less than 2% of the costs) between groups. Additionally, we did not observe differences between the two groups in BM recovery, infectious complications, side effects or the other studied parameters. In this retrospective study, the absence of differences between groups after ASCT in lymphoma and myeloma led us to believe that these drugs could be safely and effectively used for such indications without a significant impact on hospitalization costs. A prospective study should be conducted to confirm our results.
- 1 February 2013
- Vol. 33 (2) , 639-42
Double Inv(3)(q21q26), a rare but recurrent chromosomal abnormality in myeloid hemopathies.
Inv(3)(q21q26)/t(3;3)(q21;q26) is a feature of a distinctive entity of acute myeloid leukemia (AML) associated with normal or elevated platelet count, atypical megakaryocytes and multilineage dysplasia in the bone marrow, as well as minimal to no response to chemotherapy and poor clinical outcome. The presence of an inversion on both chromosome 3s is a rare event, as only eight cases have been reported in the literature. Recently, we identified two patients with AML carrying a double inv(3)(q21q26). Using librairies of bacterial artificial chromosome clones mapping to bands 3q21 and 3q26, we found that the regions in which the breakpoints occurred were different in both patients, but located in the same restricted areas in each patient. Although it cannot be excluded that inversion occurred independently on both chromosome 3s, it is more likely that the presence of a double inv(3) is the result of loss of the normal chromosome 3 followed by a duplication of the inverted chromosome, or segmental loss of heterozygosity followed by a somatic repair mechanism.
- 1 February 2013
- Vol. 33 (2) , 639-42
Double Inv(3)(q21q26), a rare but recurrent chromosomal abnormality in myeloid hemopathies.
Inv(3)(q21q26)/t(3;3)(q21;q26) is a feature of a distinctive entity of acute myeloid leukemia (AML) associated with normal or elevated platelet count, atypical megakaryocytes and multilineage dysplasia in the bone marrow, as well as minimal to no response to chemotherapy and poor clinical outcome. The presence of an inversion on both chromosome 3s is a rare event, as only eight cases have been reported in the literature. Recently, we identified two patients with AML carrying a double inv(3)(q21q26). Using librairies of bacterial artificial chromosome clones mapping to bands 3q21 and 3q26, we found that the regions in which the breakpoints occurred were different in both patients, but located in the same restricted areas in each patient. Although it cannot be excluded that inversion occurred independently on both chromosome 3s, it is more likely that the presence of a double inv(3) is the result of loss of the normal chromosome 3 followed by a duplication of the inverted chromosome, or segmental loss of heterozygosity followed by a somatic repair mechanism.
- 2 September 2012
- Published by Springer Nature in Annals of Hematology
- Vol. 92 (3) , 407-409
Pegylated interferon α2a induces complete remission of acute myeloid leukemia in a postessential thrombocythemia myelofibrosis permitting allogenic stem cell transplantation
- 2 September 2012
- Published by Springer Nature in Annals of Hematology
- Vol. 92 (3) , 407-409
Pegylated interferon α2a induces complete remission of acute myeloid leukemia in a postessential thrombocythemia myelofibrosis permitting allogenic stem cell transplantation
- Open Access
- 5 January 2012
- Published by Wiley in American Journal of Hematology
- Vol. 87 (4) , 437-439
Imatinib mesylate induces massive and nonspecific aminoaciduria in cml patients
- 5 January 2012
- Published by Wiley in American Journal of Hematology
- Vol. 87 (4) , 437-439
Open AccessImatinib mesylate induces massive and nonspecific aminoaciduria in cml patients
- 26 September 2011
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 47 (6) , 874-876
Experience (1 year) of G-CSF biosimilars in PBSCT for lymphoma and myeloma patients
- 26 September 2011
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 47 (6) , 874-876
Experience (1 year) of G-CSF biosimilars in PBSCT for lymphoma and myeloma patients
- Open Access
- 27 January 2011
- Published by Wiley in American Journal of Hematology
- Vol. 86 (4) , 351-352
Delayed G‐CSF stimulation after PBSCT does not seem to modify the biological parameters of bone marrow recovery
There are currently no recommendations indicating when stimulation should begin after autologous peripheral blood stem cell transplantation (PBSCT). We compared the outcome following between two treatment groups, in which daily granulocyte colony stimulating factor (G‐CSF) administration began on either the fifth or the eighth day after PBSCT in lymphoma and myeloma patients. We studied eight clinical parameters: number of G‐CSF injections, number of days of hospitalization, of red blood cell or platelet transfusions; days when body temperature exceeds 38°C; days of parenteral nutrition; weight loss and hospitalization costs. We studied also four biological parameters: number of CD34+ cells, days with leucocytes less than 1 × 109/L, days with hemoglobin less than 90 g/L or with less than 50 × 109/L of platelets. There were no statistical significant differences between the study arms. It seems that delayed stimulation by G‐CSF after PBSCT is safety and does not seem to modify bone marrow recovery timing. Am. J. Hematol. 86:351–352, 2011.
- 27 January 2011
- Published by Wiley in American Journal of Hematology
- Vol. 86 (4) , 351-352
Open AccessDelayed G‐CSF stimulation after PBSCT does not seem to modify the biological parameters of bone marrow recovery
There are currently no recommendations indicating when stimulation should begin after autologous peripheral blood stem cell transplantation (PBSCT). We compared the outcome following between two treatment groups, in which daily granulocyte colony stimulating factor (G‐CSF) administration began on either the fifth or the eighth day after PBSCT in lymphoma and myeloma patients. We studied eight clinical parameters: number of G‐CSF injections, number of days of hospitalization, of red blood cell or platelet transfusions; days when body temperature exceeds 38°C; days of parenteral nutrition; weight loss and hospitalization costs. We studied also four biological parameters: number of CD34+ cells, days with leucocytes less than 1 × 109/L, days with hemoglobin less than 90 g/L or with less than 50 × 109/L of platelets. There were no statistical significant differences between the study arms. It seems that delayed stimulation by G‐CSF after PBSCT is safety and does not seem to modify bone marrow recovery timing. Am. J. Hematol. 86:351–352, 2011.
- 30 December 2010
- Published by Springer Nature in Annals of Hematology
- Vol. 90 (9) , 1111-1112
Infection by H1N1 flu virus revealing T-cell acute lymphoid leukaemia: about two cases
- 30 December 2010
- Published by Springer Nature in Annals of Hematology
- Vol. 90 (9) , 1111-1112
Infection by H1N1 flu virus revealing T-cell acute lymphoid leukaemia: about two cases
- Open Access
- 28 September 2010
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 3 (1) , 34
Acute dyspnoea and single tracheal localisation of mantle cell lymphoma
Mantle cell lymphoma is a lymphoid entity characterized by adenopathy, blood and bone marrow involment which only recurrent mucosal localisation is the lymphomatoid polyposis. Few other mucosal infiltrations have been already reported.
- 28 September 2010
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 3 (1) , 34
Open AccessAcute dyspnoea and single tracheal localisation of mantle cell lymphoma
Mantle cell lymphoma is a lymphoid entity characterized by adenopathy, blood and bone marrow involment which only recurrent mucosal localisation is the lymphomatoid polyposis. Few other mucosal infiltrations have been already reported.